Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication

Area of Science:

• Hepatology
• Virology
• Metabolic Medicine

Background:

• Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocarcinoma.
• Direct-acting antivirals (DAAs) have revolutionized HCV treatment, leading to high rates of viral eradication.
• HCV infection is associated with dysregulation of lipid and carbohydrate metabolism.

Purpose of the Study:

• To review the impact of HCV eradication on lipid and carbohydrate metabolism.
• To explore potential links between altered metabolic profiles post-HCV treatment and cerebrovascular disease risk.
• To discuss recent scientific advances in understanding HCV's metabolic effects following DAA advent.

Main Methods:

• Literature review of studies on HCV, lipid metabolism, and carbohydrate metabolism.
• Analysis of research on the effects of direct-acting antiviral therapy.
• Synthesis of current scientific understanding and identification of knowledge gaps.

Main Results:

• HCV eradication halts liver disease progression and reduces hepatocarcinoma risk.
• DAA treatment can reverse lipid and carbohydrate abnormalities in HCV patients.
• The precise impact of altered lipid profiles on cerebrovascular disease risk post-HCV eradication remains uncertain.

Conclusions:

• HCV eradication offers significant benefits for liver health and metabolic parameters.
• Further research is needed to clarify the long-term cardiovascular and cerebrovascular implications of metabolic changes after successful HCV treatment.
• Understanding these metabolic shifts is crucial for comprehensive patient management post-eradication.